Nevisense improves the rate of correct biopsy choice even after dermoscopy, according to a study conducted in Germany.
Nevisense uses electrical impedance spectroscopy (EIS), a noninvasive technology that sends a painless, very low voltage electrical current through a pigmented lesion to determine if it is benign or malignant.
The article appears in SKIN – The journal of cutaneous medicine.
“This is a very important study and results for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense even compared to dermoscopy,” says Pia Renaudin, CEO of SciBase, in a news release. “In Germany, dermoscopy is standard of care for dermatologists. The study showed that the addition of Nevisense further improved dermatologists’ clinical performance.”
One hundred and fifty one German dermatologists completed a survey that comprised 49 images of malignant melanomas, severe dysplastic nevi (SDNs), and benign pigmented skin lesions. They were asked if they would biopsy the lesion after first seeing the clinical image, then again after seeing the dermoscopic image, and again after receiving the EIS score.
Respondents significantly increased correct biopsy decisions (biopsy malignant melanomas and SDNs and forego biopsy of benign PSLs) with the addition of dermoscopy versus clinical image alone for malignant melanoma and SDN. Participants also demonstrated a statistically significant increase in correct biopsy decisions beyond the dermoscopic evaluation when integrating the EIS score for malignant melanoma, SDN, and benign lesions.
“EIS was able to further improve the rate of correct biopsy choice for malignant melanoma and SDNs even beyond dermoscopic evaluation,” the researchers conclude. “While dermoscopy worsened diagnostic accuracy for benign PSLs, EIS results were able to significantly improve decision making for these lesions as well.”
